Angiotensin receptor blockers (ARBs) offer superior protection against cardiovascular events compared to ACE inhibitors, especially in patients with established disease, new data from the REACH registry shows. The observational Reduction of Atherothrombosis for Continued Health (REACH) registry followed more than 40,000 participants who were taking either treatment, mostly for existing cardiovascular disease but also for ...
Evidence builds for ARBs over ACE inhibitors for CV risk
By Mardi Chapman
16 Mar 2017